Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CCXI

ChemoCentryx (CCXI) Stock Price, News & Analysis

ChemoCentryx logo

About ChemoCentryx Stock (NASDAQ:CCXI)

Advanced Chart

Key Stats

Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Stock News Headlines

Rishi Gupta's Net Worth
Donald Trump is about to free crypto from its chains …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
See More Headlines

CCXI Stock Analysis - Frequently Asked Questions

ChemoCentryx, Inc. (NASDAQ:CCXI) posted its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative net margin of 357.01% and a negative trailing twelve-month return on equity of 48.52%.

Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2021
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CCXI
Employees
178
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-131,760,000.00
Net Margins
-357.01%
Pretax Margin
-357.01%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Price / Cash Flow
N/A
Book Value
$4.09 per share
Price / Book
12.71

Miscellaneous

Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CCXI) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners